Citigroup’s Rani Therapeutics RANI Stock Holding History

Citigroup’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2K	Sell	2,726 -50,369	-95%	-$64.3K	﹤0.01%	5424
2025 Q4	$71.7K	Buy	+53,095	New	+$80.1K	﹤0.01%	4452
2025 Q2	–	Sell	-313	Closed	-$394	–	5855
2025 Q1	$394	Buy	+313	New	+$463	﹤0.01%	5398
2022 Q4	–	Sell	-295	Closed	-$3K	–	5924
2022 Q3	$3K	Sell	295 -82	-22%	-$869	﹤0.01%	5408
2022 Q2	$4K	Sell	377 -45	-11%	-$517	﹤0.01%	5706
2022 Q1	$6K	Sell	422 -442	-51%	-$7.33K	﹤0.01%	5767
2021 Q4	$14K	Buy	+864	New	+$19.6K	﹤0.01%	5492

Other funds holding RANI

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCP

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Citigroup's RANI Position: Q1 2026 in Review

Citigroup reduced its Rani Therapeutics (RANI) stake by 95% in Q1 2026, selling an estimated $64.3K and leaving 2,726 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5424.

Citigroup first reported a position in RANI in Q4 2021 and has held it in 7 quarters since. The position peaked at $71.7K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

Citigroup held 2,726 shares of Rani Therapeutics worth $2K as of Q1 2026.
Citigroup sold 50,369 Rani Therapeutics shares in Q1 2026, an estimated $64.3K.
Rani Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5424 holding.
Citigroup first reported a position in Rani Therapeutics in Q4 2021 and has held it in 7 quarters since.
Citigroup's Rani Therapeutics position peaked at $71.7K in Q4 2025.
74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.